Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Learn from our client, Merck & Co., the relevance of PK and ADA data in a clinical setting, impact of neutralizing antibodies on PK and more.
Listen to what our client, C4 Therapeutics has to say, about the exciting opportunity that Targeted Protein Degradation represents to Biopharma companies around the world.
Our client, Albireo, recently cleared phase-3 clinical trials for its drug Odevixibat. Learn from Albireo’s experience, how to advance molecules from discovery to the clinic in the shortest possible time.
Syngene-Baxter R& D Centre is going strong even after 10 years. Undertand from our experts, the key elements of a great research partnership in ICH Stability Studies.